(a) An infectious
agent listed in this subsection constitutes a public health emergency requiring
immediate reporting. A public, private, military, hospital, or other laboratory
performing serologic, immunologic, microscopic, molecular, biochemical, or
culture examinations or tests in this state or on samples obtained within this
state shall immediately report evidence of human infection caused by the
following agents by telephone directly to a public health agent in the
department when the infectious agent is identified or suspected by the
laboratory. The following infectious agents shall be reported under this
section:
(3)
Burkholderia
pseudomailei;
(4)
Clostridium botulinum or botulinum toxin;
(5)
Corynebacterium
diphtheriae;
(6)
Francisella tularensis;
(7) hemorrhagic fever viruses;
(8) influenza virus, suspected novel
strains;
(9) Middle East
Respiratory Syndrome (MERS) coronavirus;
(10)
Neisseria
meningitidis;
(13) rubella (measles)
virus;
(14) rubeola (measles)
virus;
(15) Severe Acute
Respiratory Syndrome coronavirus (SARS-CoV), suspected novel strains;
(16) variola (smallpox) virus;
(b) In
addition to the immediate reporting requirements of (a) of this section, a
public, private, military, hospital, or other laboratory performing serologic,
immunologic, microscopic, biochemical, or cultural examinations or tests in
this state or on samples obtained within this state shall report evidence of
human infection caused by the following agents to the department not later than
two working days after the examination or test is performed:
(1) antibiotic-resistant organisms of
national significance, including
Candida auris and
carbapenem-resistant organisms;
(3)
Bordetella
pertussis;
(4)
Borrelia burgdorferi;
(6)
Campylobacter species;
(7)
Chlamydophila
psittaci;
(8)
Chlamydia trachomatis;
(10)
Cryptosporidium species;
(12)
Diphyllobothrium
species;
(13) Shiga-toxin producing
Escherichia coli (STEC);
(14)
Echinococcus
species;
(16)
Haemophilus
ducreyi;
(17)
Haemophilus influenzae from normally sterile body fluid or
site;
(19)
hepatitis A, B, C, D, or E virus; tests that shall be reported include
(A) all reactive viral hepatitis screening
tests and associated confirmatory test results;
(B) tests used to establish the presence of
hepatitis B or C viruses, including virologic, nucleic acid (DNA or RNA), or
other viral toad detection test results, both detectable and undetectable;
and
(20) human
immunodeficiency virus (HIV); tests that shall be reported include
(A) all reactive HIV screening tests and
associated coiifirmatoiry test results, both positive and negative, for human
immunodeficiency virus infection;
(B) tests used to establish the presence of
human immunodeficiency virus, including serologic, virologic, nucleic acid (DNA
or RNA), or other viral load detection test results, both detectable and
undetectable;
(C) genotype resnlts
and associated HIV nucleotide sequence data; and
(D) CD4+ (T4) lymphocyte counts and CD4+ (T4)
percent of total lymphocytes results of any value;
(24)
Listeria
monocytogenes;
(26)
Mycobacterium
leprae;
(27)
Mycobacterium tuberculosis;
(28)
Neisseria
gonorrhoeae;
(31) Respiratory syncytial virus
(RSV);
(35)
Streptococcus
agalactiae from normally sterile body fluid or site;
(36)
Streptococcus
pneumoniae from normally sterile body fluid or site;
(37)
Streptococcus pyogenes
from normally sterile body fluid or site;
(40)
Trichinella species;
(41) varicella virus, when associated with a
death;
(43)
Yersinia
enterocolitica or Yersinia pseudotuberculosis.(c) Each report must give
(1) the date and result of the examination or
test performed;
(2) the name or
identification code sufficient to identify the patient to the health care
provider; and
(3) the date of
birth, address and telephone number, sex, race, and ethnicity of the patient
from whom the specimen was obtained and the name and address of the health care
provider for whom the examination or test was performed.
(d) When acting on the basis of information
received from a report made under this section, the public health agent shall
first attempt to contact the health care provider for whom the examination or
test was performed before contacting the patient directly.
(e) A laboratory that confirms one of the
pathogens in the following list shall submit isolates or aliquots of original
specimens to the state public health laboratory:
(1) antibiotic-resistant organisms of
national significance, including
Candida auris and
carbapenem-resistant organisms;
(5)
Burkholderia pseudomallei;
(6)
Campylobacter
species;
(7)
Clostridium
botulinum; the laboratory shall provide a sample of the organism and,
if available, a serum, stool, emesis, food, or environmental sample;
(9)
Corynebacteritmi diphtheriae;
(10)
Escherichia coli, shiga
toxin-producing;
(11)
Francisella tularensis;
(12)
Haemophilus
ducreyi;
(13)
Haemophilus influenzae from normally sterile body fluid or
site;
(14)
Listeria
monocytogenes;
(15)
Mycobacterium leprae;
(16)
Mycobacterium
tuberculosis;
(17)
Neisseria sonorrhoeae;
(18)
Neisseria meningitidis
from normally sterile body fluid or site;
(20) Severe Acute
Respiratory Syndrome corona virus (SARS-CoV), suspected novel
strains;
(22)
Streptococcus agalactiae from normally sterile body fluid or
site;
(23)
Streptococcus
pneumoniae from normally sterile body fluid or site;
(24)
Streptococcus pyogenes
from normally sterile body fluid or site;
(f) Upon the request of the division of the
department that oversees public health, a laboratory shall submit clinical
material related to an outbreak or other unusual disease not identified in this
section.
